




API
Product List



World Class Pharma Ingredients



Commercial & Commercial-Scale Products

Product	Therapeutic Segment	USDMF	CEP/E-DMF
Albuterol Sulfate/Salbutamol Sulphate	Bronchodilator	✓	CEP
Alcaftadine	Allergic Conjunctivitis	✓	N/A
Apixaban	Anticoagulant	✓	E-DMF
Aripiprazole Anhydrous	Antipsychotic	✓	CEP*
Bosentan Monohydrate	Pulmonary Artery Hypertension	✓	E-DMF
Ciprofloxacin Base	Antibacterial	✓	CEP
Ciprofloxacin Hydrochloride	Antibacterial	✓	CEP
Dabigatran Etexilate Mesylate ‡	Anticoagulant	✓	E-DMF
Deferasirox	Iron Chelator	✓	E-DMF
Donepezil Base	Alzheimer's Disease	N/A	E-DMF
Donepezil Hydrochloride	Alzheimer's Disease	✓	E-DMF
Dorzolamide Hydrochloride	Anti-Glaucoma	✓	CEP
Enalapril Maleate	Antihypertensive	✓	CEP
Entacapone	Antiparkinson Agent	✓	CEP
Escitalopram Oxalate	Antidepressant	✓	CEP*
Ezetimibe	Antihyperlipidemic	✓	E-DMF
Ipratropium Bromide	Anticholinergic	✓	CEP
Itraconazole	Antifungal	✓	CEP
Labetalol Hydrochloride	Antihypertensive	✓	CEP*
Levetiracetam	Anticonvulsant	✓	CEP
Levofloxacin Hemihydrate	Antibacterial	✓	E-DMF
Linezolid	Antibacterial	✓	E-DMF
Lurasidone Hydrochloride	Antipsychotic	✓	E-DMF
Mirtazapine	Antidepressant	✓	CEP
Moxifloxacin Hydrochloride	Antibacterial	✓	CEP*
Moxonidine	Antihypertensive	N/A	CEP
Ofloxacin	Antibacterial	✓	E-DMF
Olanzapine	Antipsychotic	✓	CEP
Propofol	Anesthetic	✓	CEP
Ramipril	Antihypertensive	✓	CEP
Rivaroxaban	Anticoagulant	✓	E-DMF
Ropinirole Base	Antiparkinson Agent	✓	E-DMF
Ropinirole Hydrochloride	Antiparkinson Agent	✓	CEP*
Salmeterol Xinafoate	Bronchodilator	✓	CEP
Sotalol Hydrochloride	Antiarrhythmic	✓	CEP
Voriconazole	Antifungal	✓	CEP

For further details visit: www.neulandlabs.com

Disclaimer: The above product list includes some products which are still under protection in India and other countries. Products covered under valid patents in India and other countries will be available for supply only after expiry of the respective patents in India and the respective country.

Development Products

Product	Therapeutic Segment	USDMF	CEP/E-DMF
Apremilast	Psoriatic Arthritis	Ⓥ	Ⓥ
Aripiprazole Monohydrate (Sterile)	Antipsychotic	Ⓥ	Ⓥ
Aripiprazole Lauroxil	Antipsychotic	Ⓟ	Ⓟ
Hydralazine (For Oral)	Antihypertensive	Ⓥ	Ⓥ
Indacaterol Maleate	Bronchodilator	Ⓥ	Ⓥ
Lacosamide ‡	Anticonvulsant	Ⓥ	Ⓥ
Olanzapine Form-II	Antipsychotic	Ⓥ	Ⓥ
Olanzapine Pamoate	Antipsychotic	Ⓟ	Ⓟ
Paliperidone Palmitate (Sterile) ‡	Antipsychotic	Ⓟ	Ⓟ
Pirfenidone	Idiopathic Pulmonary Fibrosis	Ⓥ	Ⓥ
Posaconazole	Antifungal	Ⓟ	Ⓟ
Rotigotine ‡	Antiparkinson Agent	Ⓟ	Ⓟ
Rufinamide ‡	Anticonvulsant	Ⓥ	Ⓥ
Saxagliptin ‡	Antidiabetic	Ⓥ	Ⓥ
Sugammadex ‡	Selective Relaxant Binding Agent (SRBA)	Ⓥ	Ⓥ
Ticagrelor	Platelet Aggregation Inhibitors	Ⓟ	Ⓟ

R&D Pipeline Products

Product	Therapeutic Segment
Small Molecules	
Brexipiprazole	Antipsychotic
Brivaracetam	Anticonvulsant
Cariprazine	Antipsychotic
Crisaborole	Dermatology
Lifitegrast	Ophthalmological
Sacubitril-Valsartan	Cardiovascular
Vilanterol	Bronchodilator
Peptides	
Liraglutide	Antidiabetic
Ocotreotide	Growth-Hormone Antagonist

World Class Pharma Ingredients

Our core business and operational expertise has, for over 3 decades, been the manufacturing and marketing of active pharmaceutical ingredients (APIs). During this time Neuland has become a preferred and reliable source for leading pharmaceutical companies worldwide. This is primarily due to: consistency in product quality; knowledge and ability to deal with niche chemistry; and on-time delivery performance.

The Company's strength in process development, regulatory knowledge, controlled supply chain and online project management makes Neuland an ideal API partner. Additionally, with proven experience of API manufacturing at varied scales, Neuland offers custom manufacturing solutions (CMS) as well as custom synthesis services for small molecules and peptides.

Neuland currently produces more than 75 APIs in diverse therapeutic areas with over 650 DMFs worldwide.

Our Facilities

We have recently acquired a third unit that will increase our reactor capacity by 40% over the next 2 years. This supplements our two existing world-class manufacturing facilities (both USFDA and EU GMP compliant) and state-of-the-art R&D centre.

Key features include:

- 7 production blocks in Unit 1 and 6 production blocks in Unit 2 (covering 2,800 to 4,500m² of production area) and a mini-plant for scaling up of new products
- Unit 3 is a multi-product facility and has 5 production blocks for Advanced intermediates and API manufacturing
- Total reactor volume of around 729 KL (222 KL at Unit 1, 310 KL at Unit 2 and 197 KL at Unit 3) and capable of handling a broad range of reactions and wide choice of process parameters
- Quality, EHS and compliance is at the heart of Neuland and across our facilities, with a track record of regulatory approvals (12 successful US FDA inspections)

Facilities Certification


Authority	Unit 1 Inspection	Unit 2 Inspection
USFDA (USA)	March 1997, May 2004, March 2008 (PAI for NDA), November 2010, April 2014, April 2017	June 1999, February 2002, November 2005, September 2012, August 2015
EDQM (Europe)	December 2005	June 2017
EMA (Europe)	January 2013	-
WHO	February 2018	-
CFDA (China)	December 2017	-
PMDA (Japan)	October 2008	October 2008
TGA (Australia)	-	April 2011
BfArM (Germany)	-	February 2007
AFSSAPS (France)	-	February 2012
ANVISA (Brazil)	March 2012, May 2014	April 2011, May 2013
Cofepris (Mexico)	February 2014	February 2014
KFDA (South Korea)	February 2010, July 2014	February 2012
ISO 14001:2004	July 2010, 2013	May 2010, 2013
OHSAS 18001:2007	July 2010, 2013	May 2010, 2013

Our R&D centre was USFDA inspected in 2016

For Business Development Enquiries please contact:

India: apiindia@neulandlabs.com | Japan: apijapan@neulandlabs.com | North America: apinorthamerica@neulandlabs.com
Latin America: latam@neulandlabs.com | Europe: apieurope@neulandlabs.com | Rest of the World: apirow@neulandlabs.com

India Corporate Office | Tel: +91 40 3021 1600
Japan Office | Tel: +81 3 3526 5171
USA Office | Tel: +1 888 617 9587



www.neulandlabs.com